Presepsin as Detective Marker of Sepsis in Immunodeficiency ICU Patients
Completed
- Conditions
- Immune DeficiencySepsis
- Registration Number
- NCT03881566
- Lead Sponsor
- Jongmin Lee
- Brief Summary
This is an observational study to evaluate the diagnostic and prognostic value of presepsin in the critically-ill immunocompromise patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 119
Inclusion Criteria
- Male or female aged ≥ 19 years
- Appropriate clinical data to enable classification into sepsis
- Written informed consent by the patient or legally authorized representative
- Critical illness consistent with sepsis, to be enrolled within 24 hours of presentation
Exclusion Criteria
- No informed consent
- A patient who is judged to be unable to make a voluntary decision by understanding information about this research due to cognitive vulnerability
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Area Under the Receiver Operating Characteristic Curve (ROC-AUC) of the Plasma Presepsin Concentration for Discriminating Between immunocompetent and immunocompromised patients. up to 7 days For the analysis, plasma presepsin levels on Day 0 will be used. Sepsis was made on Day 7 or day of discharge. ROC-AUC of presepsin for discriminating between immunocompromised and immunocompetent patients is compared to that of procalcitonin.
- Secondary Outcome Measures
Name Time Method survival at ICU discharge or day 28 after enrollment 28 days For the analysis, we will evaluate the association between presepsin and survival at ICU discharge or day 28 after enrollment
Trial Locations
- Locations (1)
Seoul St. Mary's Hospital
🇰🇷Seoul, Korea, Republic of